136 related articles for article (PubMed ID: 21682257)
1. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ
J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257
[TBL] [Abstract][Full Text] [Related]
2. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors.
Lu Z; Chen YH; Napolitano JB; Taylor G; Ali A; Hammond ML; Deng Q; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):199-203. PubMed ID: 22142541
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
[TBL] [Abstract][Full Text] [Related]
4. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Masson D
Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
[TBL] [Abstract][Full Text] [Related]
5. Anacetrapib: hope for CETP inhibitors?
Gurfinkel R; Joy TR
Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein.
Reinhard EJ; Wang JL; Durley RC; Fobian YM; Grapperhaus ML; Hickory BS; Massa MA; Norton MB; Promo MA; Tollefson MB; Vernier WF; Connolly DT; Witherbee BJ; Melton MA; Regina KJ; Smith ME; Sikorski JA
J Med Chem; 2003 May; 46(11):2152-68. PubMed ID: 12747787
[TBL] [Abstract][Full Text] [Related]
7. Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
Miyares MA
Ann Pharmacother; 2011 Jan; 45(1):84-94. PubMed ID: 21205945
[TBL] [Abstract][Full Text] [Related]
8. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
[TBL] [Abstract][Full Text] [Related]
9. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.
Kallashi F; Kim D; Kowalchick J; Park YJ; Hunt JA; Ali A; Smith CJ; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Peterson LB; Rosa R; Sparrow CP; Wright SD; Sinclair PJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):558-61. PubMed ID: 21094047
[TBL] [Abstract][Full Text] [Related]
10. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.
Sweis RF; Hunt JA; Kallashi F; Hammond ML; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Wright SD; Anderson MS; Sinclair PJ
Bioorg Med Chem Lett; 2011 Mar; 21(6):1890-5. PubMed ID: 21147531
[TBL] [Abstract][Full Text] [Related]
11. Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit.
Wu BJ; Shrestha S; Ong KL; Johns D; Hou L; Barter PJ; Rye KA
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):628-36. PubMed ID: 25633313
[TBL] [Abstract][Full Text] [Related]
12. Novel tetrahydrochinoline derived CETP inhibitors.
Schmeck C; Gielen-Haertwig H; Vakalopoulos A; Bischoff H; Li V; Wirtz G; Weber O
Bioorg Med Chem Lett; 2010 Mar; 20(5):1740-3. PubMed ID: 20137927
[TBL] [Abstract][Full Text] [Related]
13. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R; Bergman AJ; Jin B; Fallon M; Cote J; Van Hoydonck P; Laethem T; Gendrano IN; Van Dyck K; Hilliard D; Laterza O; Snyder K; Chavez-Eng C; Lutz R; Chen J; Bloomfield DM; De Smet M; Van Bortel LM; Gutierrez M; Al-Huniti N; Dykstra K; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2008 Dec; 84(6):679-83. PubMed ID: 18580870
[No Abstract] [Full Text] [Related]
14. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
Mantlo NB; Escribano A
J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Krishna R; Bergman AJ; Jin B; Garg A; Roadcap B; Chiou R; Dru J; Cote J; Laethem T; Wang RW; Didolkar V; Vets E; Gottesdiener K; Wagner JA
J Clin Pharmacol; 2009 Jan; 49(1):80-7. PubMed ID: 19004846
[TBL] [Abstract][Full Text] [Related]
16. The development of fatty liver is accelerated in transgenic mice expressing cynomolgus monkey cholesteryl ester transfer protein.
Blake WL; Ulrich RG; Marotti KR; Melchior GW
Biochem Biophys Res Commun; 1994 Dec; 205(2):1257-63. PubMed ID: 7802658
[TBL] [Abstract][Full Text] [Related]
17. How anacetrapib inhibits the activity of the cholesteryl ester transfer protein? Perspective through atomistic simulations.
Äijänen T; Koivuniemi A; Javanainen M; Rissanen S; Rog T; Vattulainen I
PLoS Comput Biol; 2014 Nov; 10(11):e1003987. PubMed ID: 25412509
[TBL] [Abstract][Full Text] [Related]
18. [HDL and CETP in atherogenesis].
Pöss J; Böhm M; Laufs U
Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
[TBL] [Abstract][Full Text] [Related]
19. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H
J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
